PMID- 34018826
OWN - NLM
STAT- MEDLINE
DCOM- 20210525
LR  - 20220531
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 49
IP  - 5
DP  - 2021 May
TI  - Agrin expression is correlated with tumor development and poor prognosis in 
      cholangiocarcinoma.
PG  - 3000605211009722
LID - 10.1177/03000605211009722 [doi]
LID - 03000605211009722
AB  - OBJECTIVE: This study examined the role of agrin in the development of 
      cholangiocarcinoma (CCA). METHODS: Western blotting was performed to detect the 
      expression of target genes. The correlation between agrin expression and 
      prognosis was analyzed using the Kaplan-Meier method. Proliferation, migration, 
      invasion, and tumorigenesis were examined in CCA cells and tissues using the Cell 
      Counting Kit-8 assay, cell cycle analysis, transwell migration assay, and nude 
      mouse tumorigenicity assay in vivo, respectively. RESULTS: Agrin expression was 
      significantly upregulated in CCA tissues compared with that in adjacent non-tumor 
      tissues, and agrin expression was correlated with poorer tumor characteristics 
      such as portal vein tumor thrombus, intrahepatic metastasis, and worse survival. 
      Forced agrin expression in CCA cells apparently promoted proliferation, colony 
      formation, migration, invasion, and cell cycle progression, but agrin depletion 
      had the opposite effects. Furthermore, agrin-depleted CCA cells developed fewer 
      and smaller tumors than control cells in vivo. Mechanistic analyses indicated 
      that agrin activated the Hippo signaling pathway and induced the translocation of 
      YAP to the nucleus. CONCLUSIONS: Agrin promoted CCA progression by activating the 
      Hippo signaling pathway, suggesting its promise as a target for CCA therapy.
FAU - He, Meimei
AU  - He M
AD  - Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou University, Wenzhou, 325000, Zhejiang Province, China.
FAU - Cheng, Chen
AU  - Cheng C
AD  - Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou University, Wenzhou, 325000, Zhejiang Province, China.
FAU - Tu, Junxue
AU  - Tu J
AD  - Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou University, Wenzhou, 325000, Zhejiang Province, China.
FAU - Ji, Sha-Sha
AU  - Ji SS
AD  - Department of Pharmacy, Shaoxing Traditional Chinese Medicine Hospital, Shaoxing, 
      Zhejiang Province, China.
FAU - Lou, Dan
AU  - Lou D
AUID- ORCID: 0000-0002-9269-4737
AD  - Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou University, Wenzhou, 325000, Zhejiang Province, China.
FAU - Bai, Binglong
AU  - Bai B
AD  - Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou University, Wenzhou, 325000, Zhejiang Province, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Agrin)
SB  - IM
MH  - Agrin
MH  - Animals
MH  - *Bile Duct Neoplasms/genetics
MH  - Bile Ducts, Intrahepatic
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - *Cholangiocarcinoma/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Mice
MH  - Prognosis
PMC - PMC8150497
OTO - NOTNLM
OT  - Cholangiocarcinoma
OT  - Hippo pathway
OT  - YAP
OT  - agrin
OT  - invasion
OT  - metastasis
OT  - proliferation
OT  - tumorigenesis
COIS- Declaration of conflicting interest: The authors declare that there is no 
      conflict of interest.
EDAT- 2021/05/22 06:00
MHDA- 2021/05/26 06:00
PMCR- 2021/05/21
CRDT- 2021/05/21 12:12
PHST- 2021/05/21 12:12 [entrez]
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/05/26 06:00 [medline]
PHST- 2021/05/21 00:00 [pmc-release]
AID - 10.1177_03000605211009722 [pii]
AID - 10.1177/03000605211009722 [doi]
PST - ppublish
SO  - J Int Med Res. 2021 May;49(5):3000605211009722. doi: 10.1177/03000605211009722.